Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7640293 | 1.00 | ALDH1A1 (0.34) | ALDH1A1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL3344516 | 1.00 | ALDH1A1 (0.34) | ALDH1A1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL7153508 | 1.00 | ALDH1A1 (0.34) | ALDH1A1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL28900822 | 1.00 | ALDH1A1 (0.34) | ALDH1A1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL7150013 | 1.00 | ALDH1A1 (0.34) | ALDH1A1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL28992556 | 0.87 | ALDH1A1 (0.37) | ALDH1A1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL23933730 | 0.85 | ALDH1A1 (0.39) | ALDH1A1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL3489558 | 0.85 | ALDH1A1 (0.39) | ALDH1A1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL15547653 | 0.85 | ALDH1A1 (0.39) | ALDH1A1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL1311637 | 0.85 | ALDH1A1 (0.39) | ALDH1A1KDM4EMAPTTHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3596110-B1 | BORDETELLA VACCINES COMPRISING LPS WITH REDUCED REACTOGENICITY | INTRAVACC B V (NL) | 2024-09-04 | — | — | EP | disclosed |
| CN-111819184-B | Synthetic oligosaccharide derivatives as vaccine against bordetella pertussis | 芬兰疫苗研究所 | 2024-01-12 | — | — | CN | disclosed |
| US-11291713-B2 | Bordetella vaccines comprising LPS with reduced reactogenicity | INTRAVACC B.V. (NL) | 2022-04-05 | — | — | US | disclosed |
| US-20200085933-A1 | Bordetella vaccines comprising LPS with reduced reactogenicity | De Staat der Nederlanden, vert. door de minister van VWS, Ministerie van Volksgezondheid, Welzijn en (NL) | 2020-03-19 | — | — | US | disclosed |
| EP-3003389-B1 | BORDETELLA PERTUSSIS LOS-DERIVED OLIGOSACCHARIDE WITH PERTUSSIS TOXIN GLYCOCONJUGATE AND ITS APPLICATION IN THE PROPHYLAXIS AND TREATMENT OF INFECTIONS CAUSED BY BORDETELLA PERTUSSIS | PORT POLSKI OSRODEK ROZWOJU TECH SP Z O O (PL) | 2019-02-20 | — | — | EP | disclosed |
| WO-2018167061-A1 | BORDETELLA VACCINES COMPRISING LPS WITH REDUCED REACTOGENICITY | DE STAAT DER NEDERLANDEN, VERT. DOOR DE MINISTER VAN VWS, MINISTERIE VAN VOLKSGEZONDHEID, WELZIJN EN SPORT (NL) | 2018-09-20 | — | — | WO | disclosed |
| US-9878051-B2 | Bordetella pertussis LOS-derived oligosaccharide with pertussis toxin glycoconjugate and its application in the prophylaxis and treatment of infections caused by Bordetella pertussis | WROCLAWSKIE CENTRUM BADAN EIT+ SP. Z O.O. (PL) | 2018-01-30 | — | — | US | disclosed |
| US-9616139-B2 | Conjugating amines | THE GENERAL HOSPITAL CORPORATION (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160114051-A1 | BORDETELLA PERTUSSIS LOS-DERIVED OLIGOSACCHARIDE WITH PERTUSSIS TOXIN GLYCOCONJUGATE AND ITS APPLICATION IN THE PROPHYLAXIS AND TREATMENT OF INFECTIONS CAUSED BY BORDETELLA PERTUSSIS | SIEC BADAWCZA LUKASIEWICZ- PORT POLSKI OSRODEK ROZWOJU TECHNOLOGII (PL) | 2016-04-28 | — | — | US | disclosed |
| EP-3003389-A1 | BORDETELLA PERTUSSIS LOS-DERIVED OLIGOSACCHARIDE WITH PERTUSSIS TOXIN GLYCOCONJUGATE AND ITS APPLICATION IN THE PROPHYLAXIS AND TREATMENT OF INFECTIONS CAUSED BY BORDETELLA PERTUSSIS | Wroclawskie Centrum Badan EIT + Sp. z o.o. (PL) | 2016-04-13 | — | — | EP | disclosed |
| US-9296995-B2 | Vaccines against Bordetella pertussis based on LPS glycosyltransferase mutants | DE STAAT DER NEDERLANDEN, VERT. DOOR DE MINISTER VAN VWS (NL) | 2016-03-29 | — | — | US | disclosed |
| US-20150031863-A1 | CONJUGATING AMINES | THE GENERAL HOSPITAL CORPORATION (US) | 2015-01-29 | — | — | US | disclosed |
| WO-2014195881-A1 | BORDETELLA PERTUSSIS LOS-DERIVED OLIGOSACCHARIDE WITH PERTUSSIS TOXIN GLYCOCONJUGATE AND ITS APPLICATION IN THE PROPHYLAXIS AND TREATMENT OF INFECTIONS CAUSED BY BORDETELLA PERTUSSIS | WROCŁAWSKIE CENTRUM BADAŃ EIT+ SP. Z O.O. (PL) | 2014-12-11 | — | — | WO | disclosed |
| EP-2134743-B1 | IMPROVED VACCINES AGAINST BORDETELLA PERTUSSIS BASED ON LPS GLYCOSYLTRANSFERASE MUTANTS | NEDERLANDEN STAAT (NL) | 2012-09-05 | — | — | EP | disclosed |
| US-20100291153-A1 | VACCINES AGAINST BORDETELLA PERTUSSIS BASED ON LPS GLYCOSYLTRANSFERASE MUTANTS | DE STAAT DER NEDERLANDEN, VERT. DOOR DE MINISTER VAN VWS (NL) | 2010-11-18 | — | — | US | disclosed |
| EP-2134743-A2 | IMPROVED VACCINES AGAINST BORDETELLA PERTUSSIS BASED ON LPS GLYCOSYLTRANSFERASE MUTANTS | De Staat der Nederlanden, vert. door de minister van VWS (NL) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008118015-A2 | IMPROVED VACCINES AGAINST BORDETELLA PERTUSSIS BASED ON LPS GLYCOSYLTRANSFERASE MUTANTS | DE STAAT DER NEDERLANDEN, VERT. DOOR DE MINISTER VAN VWS (NL) | 2008-10-02 | — | — | WO | disclosed |
| EP-1285003-B1 | USE OF A SECONDARY CELL WALL POLYMER OF PROCARYOTIC MICROORGANISMS | NANO S BIOTECHNOLOGIE GMBH (AT) | 2004-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160114051-A1 | BORDETELLA PERTUSSIS LOS-DERIVED OLIGOSACCHARIDE WITH PERTUSSIS TOXIN GLYCOCONJUGATE AND ITS APPLICATION IN THE PROPHYLAXIS AND TREATMENT OF INFECTIONS CAUSED BY BORDETELLA PERTUSSIS | STT3A, STT3B, ST3GAL3 | ALDH1A1 4466/4885KDM4E 4655/4885MAPT 4468/4885 |
| US-20200085933-A1 | Bordetella vaccines comprising LPS with reduced reactogenicity | LCT, LTA, ENPP2 | ALDH1A1 4084/4885KDM4E 1779/4885MAPT 4643/4885 |
| US-11291713-B2 | Bordetella vaccines comprising LPS with reduced reactogenicity | LCT, LTA, ENPP2 | ALDH1A1 4084/4885KDM4E 1779/4885MAPT 4643/4885 |
| US-20150031863-A1 | CONJUGATING AMINES | CD47, CD58, CD44 | ALDH1A1 3665/4885KDM4E 1011/4885MAPT 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.